New vaccine trial aims to shield african children from deadly salmonella
NCT ID NCT06213506
First seen May 25, 2026 · Last updated May 25, 2026
Summary
This study tests a new vaccine designed to prevent invasive nontyphoidal Salmonella (iNTS) infections, a major cause of severe illness and death in Africa, especially in young children. The trial involves 215 participants in Ghana, starting with adults, then children, and finally infants as young as 6 weeks old. Researchers are checking how safe the vaccine is and how well it triggers the body's immune defenses.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SALMONELLA INFECTIONS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
GSK Investigational Site
Kumasi, Ghana
Conditions
Explore the condition pages connected to this study.